Theranos authorized new shares that would value the laboratory startup at over $10 billion, a filing shows, three days before The Wall Street Journal detailed the company’s struggles with its blood-testing technology.
WSJ.com: WSJD, Wall Street Journal: Technology
Wed, 10/28/2015 - 6:53pm
Theranos authorized new shares that would value the laboratory startup at over $10 billion, a filing shows, three days before The Wall Street Journal detailed the company’s struggles with its blood-testing technology.